Breast cancer
Conditions
Interventions
Single-arm:Eribulin combine Pyrotinib
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Aged >= 18 years and = 70 points; (5) Sufficient bone marrow functional reserve: total number of white blood cells > 4.0 x 10^9/L, neutrophils > 2.0 x 10^9/L; platelets > 100 x 10^9/L; hemoglobin > 90 g/L; (6) Sufficient kidney function reserve: serum creatinine 44-133 µmol/L; (7) Sufficient liver function reserve: AST and ALT = 50%; (9) Expected survival period >= 12 months; (10) The pregnancy test for women of childbearing age must be negative; (11) Volunteer to join the study, sign an informed consent form, have good compliance and are willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: (1) New York Heart Association (NYHA) scores to identify heart disease patients above grade II (including grade II); (2) Severe systemic infection; (3) Known allergy or intolerance to eribulin, pyrotinib or its excipients; (4) Have used any experimental drugs, received radiotherapy, or other chemotherapeutic drugs within 30 days before the first dose of study drug was administered; (5) Pregnant or lactating women, or become pregnant during the study period or within one year after the last use of the study drug; (6) Any situation that the investigator believes to participate in the trial is not in the subjects' best interests (for example, endangering their health) or that would hinder the evaluation of the trial program.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Duration of remission;Overall survival;Safety; | — |
Countries
China
Contacts
Public ContactZhenchuan Song
The Fourth Hospital of Hebei Medical University
Outcome results
None listed